Navajo Department of Health
Health Advisory Notice (HAN)
CDC and FDA Recommended a Pause of the Johnson and Johnson COVID-19 Vaccine
April 13, 2021

WINDOW ROCK, AZ – The Navajo Department of Health and Health Command Operations Center are issuing an advisory of the Johnson & Johnson COVID-19 vaccine. On April 13, 2021, the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) issued a joint press release to recommend a pause in administering the vaccine. The advisory is to inform Navajo citizens of the recommendation to pause vaccine administration.

More than 6.8 million doses of Johnson & Johnson vaccine have been administered in the U.S. The CDC and FDA are investigating six (6) reported cases of a rare and severe type of blood clot that occurred after receiving the vaccine. The individuals were all women between the ages of 18 and 48 and symptoms occurred 6 to 13 days after being vaccinated. The events reported are extremely rare and further findings from the CDC and FDA review with Johnson & Johnson is forthcoming.

As a precaution, if you received the Johnson & Johnson vaccine, and experience headache, abdominal pain, leg pain, or shortness of breath within the three weeks after receiving the vaccine, please contact your provider immediately. People should not be concerned about mild headaches and body aches in the first few days after vaccination. Those are common, temporary side effects brought on by the immune system’s response to the vaccine.